penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
Published 3 years ago • 1.4K plays • Length 5:00Download video MP4
Download video MP3
Similar videos
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
7:27
polaris: palbociclib for bipoc patients with her2-negative breast cancer
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
7:09
palbociclib endocrine therapy vs capecitabine for hr-positive her2-negative breast cancer: pearl
-
4:28
asco 2023 highlights in breast cancer: natalee, monarche, and penelope-b
-
6:47
palbociclib: single-agent or in combination for the treatment of breast cancer
-
9:54
palbociclib endocrine therapy for hormone-positive her2-negative metastatic breast cancer: 5 cases
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
2:46
ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
-
3:07
young-pearl: palbociclib plus exemestane and ofs in hr /her2- breast cancer
-
1:29
capitello-292: capivasertib, palbociclib, and fulvestrant for hr endocrine-resistant breast cancer
-
4:40
ameera-1 updates: amcenestrant plus palbociclib for patients with er /her2– advanced breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
1:45
real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
-
2:21
palbociclib with adjuvant endocrine therapy in early breast cancer - pallas study